155 related articles for article (PubMed ID: 27140858)
1. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
[TBL] [Abstract][Full Text] [Related]
3. Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.
Narayanan P; Shen L; Curtis BR; Bourdon MA; Nolan JP; Gupta S; Hoffmaster C; Zhou F; Christian B; Schaubhut JL; Greenlee S; Burel SA; Witztum JL; Engelhardt JA; Henry SP
Toxicol Sci; 2018 Aug; 164(2):613-626. PubMed ID: 29846725
[TBL] [Abstract][Full Text] [Related]
4. Complement C3d/C4d Deposition on Platelets Correlates with 2'-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys.
Shen L; Wong A; Oneda S; Curtis BR; Schroeder J; Zanardi T; Engelhardt JA; Henry SP; Narayanan P
Nucleic Acid Ther; 2023 Jun; 33(3):209-225. PubMed ID: 37093125
[TBL] [Abstract][Full Text] [Related]
5. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.
Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ
J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP
Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.
Henry SP; Jagels MA; Hugli TE; Manalili S; Geary RS; Giclas PC; Levin AA
Nucleic Acid Ther; 2014 Oct; 24(5):326-35. PubMed ID: 25093529
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
10. Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.
Crooke ST; Baker BF; Kwoh TJ; Cheng W; Schulz DJ; Xia S; Salgado N; Bui HH; Hart CE; Burel SA; Younis HS; Geary RS; Henry SP; Bhanot S
Mol Ther; 2016 Oct; 24(10):1771-1782. PubMed ID: 27357629
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
Advani R; Lum BL; Fisher GA; Halsey J; Geary RS; Holmlund JT; Kwoh TJ; Dorr FA; Sikic BI
Invest New Drugs; 2005 Oct; 23(5):467-77. PubMed ID: 16133798
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
[TBL] [Abstract][Full Text] [Related]
13. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.
Henry SP; Beattie G; Yeh G; Chappel A; Giclas P; Mortari A; Jagels MA; Kornbrust DJ; Levin AA
Int Immunopharmacol; 2002 Nov; 2(12):1657-66. PubMed ID: 12469940
[TBL] [Abstract][Full Text] [Related]
14. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.
Henry SP; Bolte H; Auletta C; Kornbrust DJ
Toxicology; 1997 Jun; 120(2):145-55. PubMed ID: 9184201
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2.
Zanardi TA; Han SC; Jeong EJ; Rime S; Yu RZ; Chakravarty K; Henry SP
J Pharmacol Exp Ther; 2012 Nov; 343(2):489-96. PubMed ID: 22915769
[TBL] [Abstract][Full Text] [Related]
18. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
[TBL] [Abstract][Full Text] [Related]
20. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates.
Guimond A; Viau E; Aubé P; Renzi PM; Paquet L; Ferrari N
Pulm Pharmacol Ther; 2008 Dec; 21(6):845-54. PubMed ID: 18761414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
